Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > topotecan

Topotecan (Hycamtin) : GlaxoSmithKline : Chemotherapeutic agent

Topotecan (Hycamtin) Active in First-Line Combo Treatment with Carboplatin in Advanced NSCLC (Doctor's Guide)
Reports results of a study presented at the 9th World Congress on Lung Cancer that found treatment with topotecan (Hycamtin) in combination with carboplatin, is an active, first-line agent in the treatment of advanced NSCLC. [9/00]

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients with Chemosensitive SCLC (Journal of Clinical Oncology)
Abstract of a study published in the 3/01 issue of the Journal of Clinical Oncology that found oral topotecan to be similar in efficacy to intravenous (IV) topotecan in the treatment of patients with relapsed SCLC, sensitive to first-line chemotherapy, with less grade 4 neutropenia and greater convenience of administration. [3/01]

Understanding Hycamtin (SmithKline Beecham)
Frequently-asked questions about Hycamtin (topotecan), including possible side effects.

Role of Topotecan in the Treatment of Small Cell Lung Cancer (The Oncologist)
by Julie R. Brahmer and David S. Ettinger
v.3, no.1 The Oncologist (February 1998): 11-14
Reviews the role of topotecan in the treatment of SCLC. Notes that as a first-line agent in chemotherapy-naive patients with extensive SCLC, topotecan has a 39% response rate and as a second-line agent in patients with "sensitive" or "refractory" disease, the response rate is greater than 38% and less than 10%, respectively. The combination of topotecan and paclitaxel exhibits a promising overall response rate of 92% in chemotherapy-naive patients with extensive SCLC. Recommends further studies of topotecan in combination with other agents and in combination with radiation therapy. [2/98]


Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 27-Apr-2011
Karen Parles, MLS Editor